Loading...
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cance...
Na minha lista:
| Udgivet i: | Lancet Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Lancet Pub. Group
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555437/ https://ncbi.nlm.nih.gov/pubmed/28642008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30318-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|